ZERO WORLD RESEARCHLiterature database on amino acids & organic acids

Affinity Purification and Comparative Biosensor Analysis of Citrulline-Peptide Specific Antibodies in Rheumatoid Arthritis

Szarka E, Aradi P, Huber K, et al.
Study designDesign not determined
SubjectUnknown

Record checks

Study design
Design not determined
Subject
Unknown
Publication year
Not recorded
Source
doi.org
Abstract display
Shown here
Publication status
Unknown
Status checked
17 Aug 2026
Collected
3 Aug 2026
Freshness
Current
Review stage
Manual review pending
Record status
Published

Publication-status notice

Publication status: Unknown

Europe PMC lookup failed; publication status remains unknown.

View status evidence →

Abstract

Background: : In rheumatoid arthritis (RA), anti-citrullinated protein/peptide antibodies (ACPAs) are responsible for disease onset and progression, however, our knowledge is limited on ligand binding affinities of autoantibodies with different citrulline-peptide specificity. Methods:: Citrulline-peptide specific ACPA IgGs were affinity purified and tested by ELISA. Binding affinities of ACPA IgGs and serum antibodies were compared by surface plasmon resonance (SPR) analysis. Bifunctional nanoparticles harboring a multi-epitope citrulline-peptide and a complement activating peptide were used to induce selective depletion of ACPA producing B cells. Results:: KD values of affinity purified ACPA IgGs varies between 10-6-10-8 M and inversely correlate with disease activity. Based on their cross-reaction with citrulline-peptides we designed a novel multi-epitope peptide, containing Cit-Gly and Ala-Cit motifs in two-two copies, separated with a short, neutral spacer. This peptide detects antibodies in RA sera with 66 % sensitivity and 98 % specificity in ELISA and is recognized by 90% of RA sera, while none of the healthy samples in SPR. When coupled to nanoparticles, the multi-epitope peptide specifically targets and depletes ACPA producing B cells ex vivo. Conclusions:: The unique multi-epitope peptide designed on the basis of ACPA cross-reactivity might be suitable to develop better diagnostics and novel therapies for RA.

DOI 10.20944/preprints201801.0012.v1

View source →